Yukun Cui
Overview
Explore the profile of Yukun Cui including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
855
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Pan H, Peng Z, Lin J, Ren X, Zhang G, Cui Y
Cancer Sci
. 2018 Oct;
109(12):3794-3804.
PMID: 30290049
The transcription factor forkhead box C1 (FOXC1) has recently been proposed as a crucial regulator of triple-negative breast cancer (TNBC) and associated with TNBC metastasis. However, the mechanism of FOXC1...
32.
Jin L, Han B, Siegel E, Cui Y, Giuliano A, Cui X
Cancer Biol Ther
. 2018 Mar;
19(10):858-868.
PMID: 29580128
Distant metastasis accounts for the vast majority of deaths in patients with cancer. Breast cancer exhibits a distinct metastatic pattern commonly involving bone, liver, lung, and brain. Breast cancer can...
33.
Hong C, Li T, Zhang F, Wu X, Chen X, Cui X, et al.
Oncol Lett
. 2017 Nov;
14(5):5379-5385.
PMID: 29113172
The 52-kDa FK506-binding protein (FKBP52), a regulator of steroid hormone receptor signaling, is potentially involved in a variety of hormone-dependent cancer types. The present study investigated the expression and clinical...
34.
Jin Y, Han B, Chen J, Wiedemeyer R, Orsulic S, Bose S, et al.
Ann Surg Oncol
. 2014 Aug;
21 Suppl 4:S758-66.
PMID: 25124473
Background: Human basal-like breast cancer (BLBC) has a poor prognosis and is often identified by expression of the epidermal growth factor receptor (EGFR). BLBC remains a major clinical challenge because...
35.
Herynk M, Selever J, Thirugnanasampanthan J, Cui Y, Fuqua S
Cancer Treat Res
. 2011 Apr;
147:1-16.
PMID: 21461833
No abstract available.
36.
Herynk M, Hopp T, Cui Y, Niu A, Corona-Rodriguez A, Fuqua S
Breast Cancer Res Treat
. 2009 Oct;
122(2):381-93.
PMID: 19842032
Estrogen receptor alpha (ERalpha) is highly regulated through multiple mechanisms including cell signaling, posttranslational modifications, and protein-protein interactions. We have previously identified a K303R ERalpha mutation within the hinge region...
37.
De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, et al.
Breast Cancer Res Treat
. 2009 Jun;
121(1):1-11.
PMID: 19533338
Although the androgen receptor (AR) is a known clinical target in prostate cancer, little is known about its possible role in breast cancer. We have investigated the role of AR...
38.
Barone I, Cui Y, Herynk M, Corona-Rodriguez A, Giordano C, Selever J, et al.
Cancer Res
. 2009 Jun;
69(11):4724-32.
PMID: 19487288
Aromatase inhibitors (AI) are rapidly becoming the first choice for hormonal treatment of estrogen receptor-alpha (ERalpha)-positive breast cancer in postmenopausal women. However, de novo and acquired resistance frequently occurs. We...
39.
Giordano C, Cui Y, Barone I, Ando S, Mancini M, Berno V, et al.
Breast Cancer Res Treat
. 2009 Feb;
119(1):71-85.
PMID: 19205871
Estrogens play a crucial role in breast tumor growth, which is the rationale for the use of antiestrogens, such as tamoxifen, in women with estrogen receptor (ER)-alpha-positive breast cancer. However,...
40.
Herynk M, Parra I, Cui Y, Beyer A, Wu M, Hilsenbeck S, et al.
Clin Cancer Res
. 2007 Jun;
13(11):3235-43.
PMID: 17545528
Purpose: Estrogen receptor alpha (ERalpha) predicts the natural history of breast cancer without intervening therapy. Here, we have optimized the detection of a somatic mutation, an A908G transition of ERalpha,...